Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells - PubMed (original) (raw)
. 2000 Feb 1;95(3):999-1006.
Affiliations
- PMID: 10648415
Free article
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells
T Decker et al. Blood. 2000.
Free article
Abstract
Bacterial DNA and synthetic CpG-oligodeoxynucleotides (ODNs) derived thereof have attracted attention because they activate cells of the immune system in a sequence-dependent manner. Here we investigated the potential of CpG-ODNs to cause proliferation, cytokine production, and regulation of surface molecules in human B-chronic lymphocytic leukemia (CLL) cells. CpG-ODN induced proliferation in both B-CLL cells and normal B cells; however, only B-CLL cells increased proliferative responses when CpG-ODN was added to co-cultures of CD40-ligand transfected mouse fibroblasts (CD40LF) and B cells. Production of interleukin-6 and tumor necrosis factor alpha was detectable at borderline levels, using CpG-ODN as the only stimulus. In contrast, when CpG-ODN was added to co-cultures of B cells and CD40LF, a strong increase in cytokine production occurred in B-CLL cells as well as in normal B cells. The surface molecules CD40, CD58, CD80, CD86, CD54, and MHC class I molecules were up-regulated in B-CLL cells, whereas CD95 expression was not influenced by CpG-ODN stimulation. The same pattern of surface molecule regulation was observed in normal B cells, but up-regulation of CD40 was significantly stronger in B-CLL cells. Costimulation with CpG-ODN and CD40LF resulted in further up-regulation of CD58, CD80, CD86, and MHC class I molecules. In contrast, CD95 expression induced by CD40-ligation was inhibited by CpG-ODN. CpG-ODN activated B-CLL cells acquired a strong stimulatory capacity toward T cells in allogeneic mixed lymphocyte reaction. This effect was completely inhibited by a combination of anti-CD80 and anti-CD86 monoclonal antibody. Taken together, these findings suggest the possible use of CpG-ODN for immunotherapeutic strategies in patients with B-CLL.
Similar articles
- Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H, Peschel C. Decker T, et al. Exp Hematol. 2000 May;28(5):558-68. doi: 10.1016/s0301-472x(00)00144-2. Exp Hematol. 2000. PMID: 10812246 - CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F, Hermann P, Nakashima K, Matsukawa S, Sakai K, Bacon KB. Gantner F, et al. Eur J Immunol. 2003 Jun;33(6):1576-85. doi: 10.1002/eji.200323444. Eur J Immunol. 2003. PMID: 12778475 - Regulation of CD80/B7-1 and CD86/B7-2 molecule expression in human primary acute myeloid leukemia and their role in allogenic immune recognition.
Costello RT, Mallet F, Sainty D, Maraninchi D, Gastaut JA, Olive D. Costello RT, et al. Eur J Immunol. 1998 Jan;28(1):90-103. doi: 10.1002/(SICI)1521-4141(199801)28:01<90::AID-IMMU90>3.0.CO;2-5. Eur J Immunol. 1998. PMID: 9485189 - Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.
Decker T, Peschel C. Decker T, et al. Leuk Lymphoma. 2001 Jul;42(3):301-7. doi: 10.3109/10428190109064586. Leuk Lymphoma. 2001. PMID: 11699394 Review. - CD40 ligand in CLL pathogenesis and therapy.
Schattner EJ. Schattner EJ. Leuk Lymphoma. 2000 May;37(5-6):461-72. doi: 10.3109/10428190009058499. Leuk Lymphoma. 2000. PMID: 11042507 Review.
Cited by
- In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R. Brody JD, et al. J Clin Oncol. 2010 Oct 1;28(28):4324-32. doi: 10.1200/JCO.2010.28.9793. Epub 2010 Aug 9. J Clin Oncol. 2010. PMID: 20697067 Free PMC article. Clinical Trial. - Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, Chen W. Liang X, et al. Blood. 2010 Jun 17;115(24):5041-52. doi: 10.1182/blood-2009-03-213363. Epub 2010 Mar 25. Blood. 2010. PMID: 20339095 Free PMC article. - p53 and cell cycle independent dysregulation of autophagy in chronic lymphocytic leukaemia.
Groves MJ, Johnson CE, James J, Prescott AR, Cunningham J, Haydock S, Pepper C, Fegan C, Pirrie L, Westwood NJ, Coates PJ, Ganley IG, Tauro S. Groves MJ, et al. Br J Cancer. 2013 Oct 29;109(9):2434-44. doi: 10.1038/bjc.2013.601. Epub 2013 Oct 3. Br J Cancer. 2013. PMID: 24091621 Free PMC article. - Disrupting pro-survival and inflammatory pathways with dimethyl fumarate sensitizes chronic lymphocytic leukemia to cell death.
Mantione ME, Meloni M, Sana I, Bordini J, Del Nero M, Riba M, Ranghetti P, Perotta E, Ghia P, Scarfò L, Muzio M. Mantione ME, et al. Cell Death Dis. 2024 Mar 18;15(3):224. doi: 10.1038/s41419-024-06602-z. Cell Death Dis. 2024. PMID: 38494482 Free PMC article. - Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia.
Slezak AJ, Chang K, Beckman TN, Refvik KC, Alpar AT, Lauterbach AL, Solanki A, Kwon JW, Gomes S, Mansurov A, Hubbell JA. Slezak AJ, et al. Blood Adv. 2024 Apr 9;8(7):1747-1759. doi: 10.1182/bloodadvances.2023012529. Blood Adv. 2024. PMID: 38324726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials